Statistical and practical considerations in planning and conduct of dose-optimization trials

被引:7
作者
Yuan, Ying [1 ,3 ]
Zhou, Heng [2 ]
Liu, Suyu [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr Houston, Dept Biostat, Houston, TX USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA
[3] Univ Texas MD Anderson Canc Ctr Houston, Dept Biostat, Houston, TX 77030 USA
关键词
Optimal dose; benefit-risk trade-off; Project Optimus; adaptive design; CONTINUAL REASSESSMENT METHOD; II CLINICAL-TRIALS; ADAPTIVE RANDOMIZATION; TARGETED THERAPIES; ORDINAL TOXICITY; INTERVAL DESIGN; FINDING DESIGN; PHASE; EFFICACY; SELECTION;
D O I
10.1177/17407745231207085
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The U.S. Food and Drug Administration launched Project Optimus with the aim of shifting the paradigm of dose-finding and selection toward identifying the optimal biological dose that offers the best balance between benefit and risk, rather than the maximum tolerated dose. However, achieving dose optimization is a challenging task that involves a variety of factors and is considerably more complicated than identifying the maximum tolerated dose, both in terms of design and implementation. This article provides a comprehensive review of various design strategies for dose-optimization trials, including phase 1/2 and 2/3 designs, and highlights their respective advantages and disadvantages. In addition, practical considerations for selecting an appropriate design and planning and executing the trial are discussed. The article also presents freely available software tools that can be utilized for designing and implementing dose-optimization trials. The approaches and their implementation are illustrated through real-world examples.
引用
收藏
页码:273 / 286
页数:14
相关论文
共 75 条
[1]   Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy [J].
Agrawal, Shruti ;
Feng, Yan ;
Roy, Amit ;
Kollia, Georgia ;
Lestini, Brian .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
[2]  
[Anonymous], RAND PAHS 2 3 MULT C
[3]   Dose-finding based on multiple toxicities in a soft tissue sarcoma trial [J].
Bekele, BN ;
Thall, PF .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2004, 99 (465) :26-35
[4]   The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes [J].
Braun, TA .
CONTROLLED CLINICAL TRIALS, 2002, 23 (03) :240-256
[5]   Combining multiple comparisons and modeling techniques in dose-response studies [J].
Bretz, F ;
Pinheiro, JC ;
Branson, M .
BIOMETRICS, 2005, 61 (03) :738-748
[6]   A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development [J].
Chen, Cong ;
Anderson, Keaven ;
Mehrotra, Devan V. ;
Rubin, Eric H. ;
Tse, Archie .
CONTEMPORARY CLINICAL TRIALS, 2018, 64 :238-242
[7]   A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials [J].
Chen, Zhengjia ;
Krailo, Mark D. ;
Azen, Stanley P. ;
Tighiouart, Mourad .
CONTEMPORARY CLINICAL TRIALS, 2010, 31 (05) :473-482
[8]   An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles [J].
Du, Yu ;
Yin, Jun ;
Sargent, Daniel J. ;
Mandrekar, Sumithra J. .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (02) :271-286
[9]   Dose-finding designs using a novel quasi-continuous endpoint for multipletoxicities [J].
Ezzalfani, Monia ;
Zohar, Sarah ;
Qin, Rui ;
Mandrekar, Sumithra J. ;
Le Deley, Marie-Cecile .
STATISTICS IN MEDICINE, 2013, 32 (16) :2728-2746
[10]   DROID: dose-ranging approach to optimizing dose in oncology drug development [J].
Guo, Beibei ;
Yuan, Ying .
BIOMETRICS, 2023, 79 (04) :2907-2919